• Williams Fernandes Barra
  • Samia Demachki
  • Geraldo Ishak
  • Paulo Pimentel de Assumpção


Recent decades have witnessed a progressive reduction in the incidence and mortality of gastric cancer worldwide. This trend mainly relates to the reduction of intestinal-type gastric cancer and could be attributed to the knowledge and control of risk factors such as Helicobacter pylori and other dietary and environmental factors. The diffuse gastric cancer maintains a relatively stable incidence. Considering that hereditary diffuse gastric cancer (HDGC), determined by germline pathogenic mutations in the CDH1 gene, is responsible for a small portion of diffuse gastric cancer cases, the underlying cause that would explain the unchanged incidence of diffuse gastric cancer is largely unknown. Further investigations into the relationship between risk factors and diffuse gastric cancer tumorigenesis may lead to improvements in cancer prevention, screening, and treatment.


Gastric cancer diffuse epidemiology CDH1 Hereditary diffuse gastric cancer 


  1. 1.
    Global Burden of Disease Cancer Collaboration. The global burden of cancer 2013. JAMA Oncol. 2015;1(4):505–27.CrossRefPubMedCentralGoogle Scholar
  2. 2.
    Parkin DM. Epidemiology of cancer: global patterns and trends. Toxicol Lett. 1998;102–103:227–34.CrossRefPubMedGoogle Scholar
  3. 3.
    Corso G, et al. History, pathogenesis, and management of familial gastric cancer: original study of John XXIII’s family. Biomed Res Int. 2013;2013, 385132Google Scholar
  4. 4.
    Nagini S. Carcinoma of the stomach: a review of epidemiology, pathogenesis, molecular genetics and chemoprevention. World J Gastrointest Oncol. 2012;4(7):156–69.CrossRefPubMedPubMedCentralGoogle Scholar
  5. 5.
    Bertuccio P, et al. Recent patterns in gastric cancer: a global overview. Int J Cancer. 2009;125(3):666.CrossRefPubMedGoogle Scholar
  6. 6.
    Anderson WF, et al. Age-specific trends in incidence of noncardia gastric cancer in US adults. JAMA. 2010;303(17):1723.CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    Pernot S, Voron T, Perkins G, et al. Signet-ring cell carcinoma of the stomach: Impact on prognosis and specific therapeutic challenge. World J Gastroenterol. 2015;21(40):11428–38.CrossRefPubMedPubMedCentralGoogle Scholar
  8. 8.
    Laurén P. The two histological main types of gastric carcinoma: diffuse and so-called intestinal-type carcinoma. An attempt at a histo-clinical classification. Acta Pathol Microbiol Scand. 1965;64:31–49.CrossRefPubMedGoogle Scholar
  9. 9.
    Lauwers GY, Carneiro F, Graham DY, et al. Gastric carcinoma. In: Bosman FT, Carneiro F, Hruban RH, Theise ND, editors. WHO classification of tumours of the digestive system. 4th ed. Lyon: IARC; 2010. p. 48–58.Google Scholar
  10. 10.
    The Cancer Genome Atlas Research Network. Comprehensive molecular characterization of gastric adenocarcinoma. Nature. 2014;513:202–9.CrossRefGoogle Scholar
  11. 11.
    Chen YC, Fang WL, Wang RF, et al. Clinicopathological variation of Lauren classification in gastric cancer. Pathol Oncol Res. 2016;22(1):197–202.CrossRefPubMedGoogle Scholar
  12. 12.
    Jaehn P, Holleczek B, Becher H, Winkler V. Histologic types of gastric cancer among migrants from the former Soviet Union and the general population in Germany: what kind of prevention do we need? Eur J Gastroenterol Hepatol. 2016;28(8):863–70.CrossRefPubMedGoogle Scholar
  13. 13.
    International Agency for Research on Cancer. Schistosomes, liver flukes and Helicobacter pylori. IARC Monogr Eval Carcinog Risk Hum. 1994;61:1–241.Google Scholar
  14. 14.
    Uemura N, Okamoto S, Yamamoto S, et al. Helicobacter pylori infection and the development of gastric cancer. N Engl J Med. 2001;345(11):784–9.CrossRefPubMedGoogle Scholar
  15. 15.
    Carneiro F, Charlton A, Huntsman DG. Hereditary diffuse gastric cancer. In: Bosman FT, Carneiro F, Hruban RH, Theise ND, editors. WHO classification of tumours of the digestive system. 4th ed. Lyon: IARC; 2010. p. 59–63.Google Scholar
  16. 16.
    Ford AC, Forman D, Hunt R, Yuan Y, Moayyedi P. Helicobacter pylori eradication for the prevention of gastric neoplasia. Cochrane Database Syst Rev. 2015;(7):CD005583.
  17. 17.
    Take S, Mizuno M, Ishiki K, et al. The long-term risk of gastric cancer after the successful eradication of Helicobacter pylori. J Gastroenterol. 2011;46(3):318–24.CrossRefPubMedGoogle Scholar
  18. 18.
    Sasco AJ, Secretan MB, Straif K. Tobacco smoking and cancer: a brief review of recent epidemiological evidence. Lung Cancer. 2004;45(Suppl 2):S3–9.CrossRefPubMedGoogle Scholar
  19. 19.
    González CA, Jakszyn P, Pera G, et al. Meat intake and risk of stomach and esophageal adenocarcinoma within the European Prospective Investigation Into Cancer and Nutrition (EPIC). J Natl Cancer Inst. 2006;98:345.CrossRefPubMedGoogle Scholar
  20. 20.
    Bouvard V, Loomis D, Guyton KZ, et al. Carcinogenicity of consumption of red and processed meat. Lancet Oncol. 2015;16(16):1599–600.CrossRefPubMedGoogle Scholar
  21. 21.
    Fang X, Wei J, He X, et al. Landscape of dietary factors associated with risk of gastric cancer: a systematic review and dose-response meta-analysis of prospective cohort studies. Eur J Cancer. 2015;51(18):2820–32.CrossRefPubMedGoogle Scholar
  22. 22.
    Hoang BV, Lee J, Choi IJ, et al. Effect of dietary vitamin C on gastric cancer risk in the Korean population. World J Gastroenterol. 2016;22(27):6257–67.CrossRefPubMedPubMedCentralGoogle Scholar
  23. 23.
    Zhang Z, Xu G, Ma M, Yang J, Liu X. Dietary fiber intake reduces risk for gastric cancer: a meta-analysis. Gastroenterology. 2013;145(1):113.CrossRefPubMedGoogle Scholar
  24. 24.
    Park B, Shin A, Park SK, et al. Ecological study for refrigerator use, salt, vegetable, and fruit intakes, and gastric cancer. Cancer Causes Control. 2011;22:1497.CrossRefPubMedGoogle Scholar
  25. 25.
    Yang P, Zhou Y, Chen B, et al. Overweight, obesity and gastric cancer risk: results from a meta-analysis of cohort studies. Eur J Cancer. 2009;45(16):2867–73.CrossRefPubMedGoogle Scholar
  26. 26.
    Takada K. Epstein-Barr virus and gastric carcinoma. Mol Pathol. 2000;53(5):255.CrossRefPubMedPubMedCentralGoogle Scholar
  27. 27.
    Kusano M, Toyota M, Suzuki H, et al. Genetic, epigenetic, and clinicopathologic features of gastric carcinomas with the CpG island methylator phenotype and an association with Epstein-Barr virus. Cancer. 2006;106(7):1467–79.CrossRefPubMedGoogle Scholar
  28. 28.
    Lee JH, Kim SH, Han SH, et al. Clinicopathological and molecular characteristics of Epstein-Barr virus-associated gastric carcinoma: a meta-analysis. J Gastroenterol Hepatol. 2009;24(3):354–65.CrossRefPubMedGoogle Scholar
  29. 29.
    Edgren G, Hialgrim H, Rostgaard K, et al. Risk of gastric cancer and peptic ulcers in relation to ABO blood type: a cohort study. Am J Epidemiol. 2010;172(11):1280–5.CrossRefPubMedGoogle Scholar
  30. 30.
    Guilford P, Hopkins J, Harraway J, et al. E-cadherin germline mutations in familial gastric cancer. Nature. 1998;392:402–5.CrossRefPubMedGoogle Scholar
  31. 31.
    Rashid H, Alam K, Afroze D, et al. Hypermethylation status of E-cadherin gene in gastric cancer patients in a high incidence area. Asian Pac J Cancer Prev. 2016;17(6):2757–60.PubMedGoogle Scholar
  32. 32.
    van der Post RS, Vogelaar IP, Carneiro F, et al. Hereditary diffuse gastric cancer: updated clinical guidelines with an emphasis on germline CDH1 mutation carriers. J Med Genet. 2015;52(6):361–74.CrossRefPubMedPubMedCentralGoogle Scholar
  33. 33.
    Carneiro F, Huntsman DG, Smyrk TC, et al. Model of the early development of diffuse gastric cancer in E-cadherin mutation carriers and its implications for patient screening. J Pathol. 2004;203:681–7.CrossRefPubMedGoogle Scholar
  34. 34.
    McDonald AM, Sarfati D, Baker MG, et al. Trends in Helicobacter pylori infection among Māori, Pacific, and European birth cohorts in New Zealand. Helicobacter. 2015;20(2):139–45.CrossRefPubMedGoogle Scholar
  35. 35.
    Correa P. Human gastric carcinogenesis: a multistep and multifactorial process – first American Cancer Society Award Lecture on Cancer Epidemiology and Prevention. Cancer Res. 1992;52:6735–40.PubMedPubMedCentralGoogle Scholar
  36. 36.
    Haastrup P, Paulsen MS, Zwisler JE, et al. Rapidly increasing prescribing of proton pump inhibitors in primary care despite interventions: a nationwide observational study. Eur J Gen Pract. 2014;20(4):290–3.CrossRefPubMedGoogle Scholar
  37. 37.
    Attwood SE, Ell C, Galmiche JP, et al. Long-term safety of proton pump inhibitor therapy assessed under controlled, randomised clinical trial conditions: data from the SOPRAN and LOTUS studies. Aliment Pharmacol Ther. 2015;41(11):1162–74.CrossRefPubMedGoogle Scholar
  38. 38.
    Ianiro G, Molina-Infante J, Gasbarrini A. Gastric microbiota. Helicobacter. 2015;20(Suppl 1):68–71.CrossRefPubMedGoogle Scholar
  39. 39.
    Henson DE, Dittus C, Younes M, Nguyen H, Albores-Saavedra JA. Differential trends in the intestinal and diffuse types of gastric carcinoma in the United States, 1973–2000: increase in the signet ring cell type. Arch Pathol Lab Med. 2004;128:765–70.PubMedGoogle Scholar
  40. 40.
    Wu H, Rusiecki JA, Zhu K, Potter J, Devesa SS. Stomach carcinoma incidence patterns in the United States by histologic type and anatomic site. Cancer Epidemiol Biomarkers Prev. 2009;18(7):1945–52.CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2018

Authors and Affiliations

  • Williams Fernandes Barra
    • 1
  • Samia Demachki
    • 1
  • Geraldo Ishak
    • 1
  • Paulo Pimentel de Assumpção
    • 1
  1. 1.Núcleo de Pesquisas em Oncologia, Hospital Universitário João de Barros Barreto, Universidade Federal do ParáGuamá, BelémBrazil

Personalised recommendations